BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα mal…
$2.14-8.94%
报价 2026-11-13
市值
$171.7M
EV
$131.1M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -84.4%
$2.04$13.73
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BBOTBridgeBio Oncology Therapeutics Inc. | $171.7M | -8.9% | – | 0% | – | – | – | |
| KODKodiak Sciences Inc. | $7.27B | +2.7% | +1783.3% | 0% | – | – | – | |
| TNGXTango Therapeutics, Inc. | $4.32B | +2.6% | -90.3% | 98.3% | – | – | – | |
| XNCRXencor, Inc. | $2.78B | -2.7% | +45.7% | 93.9% | – | – | – | |
| SEPNSepterna, Inc. | $2.03B | +1.8% | +149.0% | 99.4% | – | – | 16.4x | |
| NRIXNurix Therapeutics, Inc. | $1.69B | -0.8% | +700.2% | -139.4% | – | – | 4.6x | |
| ANABAnaptysBio, Inc. | $1.38B | -3.2% | -32.8% | 99% | – | 27.8x | 76.5x | |
| URGNUroGen Pharma Ltd. | $1.28B | -0.8% | +185.5% | 90.9% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $492.6M | -2.7% | +80.5% | 80.7% | – | – | – | |
| 同行中位数 | – | – | +114.7% | 92.4% | – | 27.8x | 16.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。